All News
Filter News
Found 10,130 articles
-
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
3/26/2024
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
-
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
3/26/2024
Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.
-
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
3/26/2024
BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.
-
Keymed Biosciences Announces 2023 Annual Results and Business Updates
3/26/2024
Keymed Biosciences Inc. (HKEX: 02162) today announced its 2023 annual results, along with recent pipeline highlights and corporate updates.
-
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
3/25/2024
AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
-
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
3/25/2024
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
-
Clinical Trials Market Size to Gain USD 83.55 Billion by 2032
3/21/2024
The global clinical trials market was evaluated at USD 51.17 billion in 2023 and is expected to attain around USD 83.55 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.
-
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
3/21/2024
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results.
-
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
3/21/2024
Innate Pharma SA reported its consolidated financial results for the year ending December 31, 2023.
-
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
3/21/2024
Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival and progression-free survival for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer.
-
The FDA took center stage last week as it approved the first-ever MASH therapy and considered additional approvals for CAR-T therapies, whose safety the agency has been investigating since last year.
-
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
3/20/2024
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
-
Cartherics Executes Option Agreement with the Ohio State University
3/20/2024
The Company will utilize its proprietary induced pluripotent stem cell (iPSC)-derived NK cells to conduct the evaluation. Subject to the results, Cartherics will then exercise the option to negotiate a commercial license to the IP.
-
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
3/20/2024
2seventy bio, Inc., announced that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors, effective immediately.
-
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
3/20/2024
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab).
-
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
3/20/2024
BioLineRx Ltd. today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.
-
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
3/20/2024
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET.
-
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
3/20/2024
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”) today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
-
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/20/2024
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
-
By votes of 11-0 and 8-3, respectively, an FDA advisory committee Friday deemed the risks of early death for both Johnson & Johnson’s Carvykti and Bristol Myers Squibb’s Abecma acceptable.